Pembrolizumab is a monoclonal antibody that targets the PD-1 receptor on T-cells. By inhibiting this receptor, pembrolizumab helps the immune system recognize and attack cancer cells more effectively. It has been approved for various cancers, but its role in NSCLC was solidified through the results of Keynote 024.
